Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.60 |
| ▸ | NPC1 | O15118 | 6/20 | 0.60 |
| ▸ | RAB9A | P51151 | 6/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 6/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | TYR | P14679 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.52 |
| ▸ | IAPP | P10997 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8545871 | 1.00 | KDM4E (0.72) | KDM4EMAPK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL13476341 | 0.86 | TDP1 (0.57) | KDM4EMAPK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL11253548 | 0.86 | KDM4E (0.75) | KDM4EMAPK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL11253542 | 0.86 | KDM4E (0.75) | KDM4EMAPK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1359335 | 0.85 | GLA (0.77) | KDM4EMAPK1GLATDP1LMNA | |
| SCHEMBL1359336 | 0.85 | GLA (0.77) | KDM4EMAPK1GLATDP1LMNA | |
| SCHEMBL9785216 | 0.84 | KDM4E (0.72) | KDM4EMAPK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1711780 | 0.84 | KDM4E (1.00) | KDM4EMAPK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL819055 | 0.84 | KDM4E (1.00) | KDM4EMAPK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL12894656 | 0.82 | KDM4E (0.70) | KDM4EMAPK1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708346-B2 | Treatment and prevention of neuropathic pain with P2Y14 antagonists | SAINT LOUIS UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230159569-A1 | DUAL HDAC6/PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-05-25 | — | — | US | disclosed |
| US-7576079-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2009-08-18 | — | — | US | disclosed |
| US-20090087409-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2009-04-02 | — | — | US | disclosed |
| EP-0691579-B1 | Electrophotographic elements and soluble cyclic sulfone electron transport agents | EASTMAN KODAK CO (US) | 1998-11-04 | — | — | EP | disclosed |
| US-5618950-A | Electrophotographic elements and soluble cyclic sulfone electron transport agents | EASTMAN KODAK COMPANY (US) | 1997-04-08 | — | — | US | disclosed |
| US-5500317-A | DICYANO-SULFONE COMPOUND | EASTMAN KODAK COMPANY (US) | 1996-03-19 | — | — | US | disclosed |
| EP-0691579-A1 | Electrophotographic elements and soluble cyclic sulfone electron transport agents | EASTMAN KODAK COMPANY (US) | 1996-01-10 | — | — | EP | disclosed |
| US-4261988-A | ANTICHOLESTEROL AGENTS USED IN ANIMAL HUSBANDRY | BAYER AKTIENGESELLSCHAFT (DE) | 1981-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090087409-A1 | Viral Polymerase Inhibitors | NR2C2, NR4A1, MED25 | KDM4E 3438/4885MAPK1 1244/4885SMN1; SMN2 1027/4885 |
| US-11708346-B2 | Treatment and prevention of neuropathic pain with P2Y14 antagonists | P2RY14, P2RY4, P2RY13 | KDM4E 4599/4885MAPK1 2687/4885SMN1; SMN2 482/4885 |
| US-20230159569-A1 | DUAL HDAC6/PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF | HDAC6, PSMG3, PSMB2 | KDM4E 1954/4885MAPK1 3408/4885SMN1; SMN2 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.